Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23161990.
- Also identified by DOI 10.1126/science.1226338 and PMC identifier 3660151.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nanoparticle-based drug delivery systems have been developed to improve the efficacy and reduce the systemic toxicity of a wide range of drugs. Although clinically approved nanoparticles have consistently shown value in reducing drug toxicity, their use has not always translated into improved clinical outcomes. This has led to the development of "multifunctional" nanoparticles, where additional capabilities like targeting and image contrast enhancement are added to the nanoparticles. However, additional functionality means additional synthetic steps and costs, more convoluted behavior and effects in vivo, and also greater regulatory hurdles. The trade-off between additional functionality and complexity is the subject of ongoing debate and the focus of this Review.
Medical subject headings
- Animals
- Biomarkers, Tumor
- Biomarkers, Tumor/metabolism
- Cardiovascular Diseases
- Cardiovascular Diseases/diagnosis
- Cardiovascular Diseases/drug therapy
- Clinical Trials as Topic
- Cost-Benefit Analysis
- Diagnostic Imaging
- Diagnostic Imaging/economics
- Drug Delivery Systems
- Drug Delivery Systems/economics
- Humans
- Mice
- Molecular Targeted Therapy
- Molecular Targeted Therapy/methods
- Nanoparticles
- Nanoparticles/chemistry
- Nanoparticles/economics
- Nanoparticles/therapeutic use
- Neoplasms
- Neoplasms/diagnosis
- Neoplasms/drug therapy
- Transcytosis